Ted Schroeder Joins Phathom Pharmaceuticals Board of Directors
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a biopharmaceutical company developing treatments for gastrointestinal conditions, has recently appointed Ted Schroeder to its Board of Directors. This addition is expected to usher in a new chapter for the company, particularly as it works towards achieving its core objectives.
A Seasoned Leader with Extensive Experience
Ted Schroeder comes equipped with over thirty years of experience in the biopharmaceutical sector. His expertise in leading companies through complex commercial transitions, building successful teams, and bringing innovative therapies to market makes him an invaluable resource for Phathom Pharmaceuticals. Michael Cola, Chairman of the Board at Phathom, expressed enthusiasm about Schroeder joining the team during a crucial period for the company.
Schroeder's Track Record of Success
Throughout his illustrious career, Ted Schroeder has held key leadership positions, including Chief Executive Officer at Nabriva Therapeutics, where he served from 2018 until 2023. His strategic vision helped navigate Nabriva through pivotal changes, especially after the acquisition of Zavante Therapeutics. He is also co-founder of Cadence Pharmaceuticals, where he successfully led the company to a $1.4 billion acquisition by Mallinckrodt Pharmaceuticals in 2014.
Contributions to the Biopharmaceutical Community
In addition to his executive roles, Schroeder has served on the boards of various public and private life sciences firms, such as Cidara Therapeutics, Otonomy, and Collegium Pharmaceutical. His leadership and innovative strategies have been recognized across the industry, including receiving the EY Entrepreneur of the Year award in 2014 for the San Diego region.
Phathom Pharmaceuticals and its Mission
Phathom Pharmaceuticals is dedicated to the development and commercialization of novel treatments targeting gastrointestinal diseases. One standout achievement is their in-licensed drug, vonoprazan, a potassium-competitive acid blocker known in the U.S. market as VOQUEZNA. This product plays a crucial role in treating various forms of gastroesophageal reflux disease (GERD) and has been pivotal in the company’s growth strategy.
Innovative Treatments for Patients
VOQUEZNA is marketed for managing heartburn related to non-erosive GERD and for healing erosive GERD. The company also offers VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, combinations designed to tackle H. pylori infections in adults. These innovative products are a testament to Phathom's commitment to advancing gastrointestinal health and offering valuable options to patients.
Looking Forward
The addition of Ted Schroeder to the board is seen as a significant milestone for Phathom Pharmaceuticals. With a focus on enhancing their commercial momentum, the company aims to leverage Schroeder's vast experience in the biopharmaceutical industry to navigate future challenges and opportunities.
Engagement with Stakeholders
As the company evolves, maintaining open lines of communication with investors and stakeholders remains a priority. Phathom Pharmaceuticals is dedicated to transparency and providing updates as they make strides forward in their mission. Interested parties can reach out through the provided contact channels for inquiries.
Frequently Asked Questions
What experience does Ted Schroeder bring to Phathom Pharmaceuticals?
Ted Schroeder has over three decades in the biopharmaceutical industry, with a strong track record in leading companies toward commercial success and innovative drug development.
What is the primary product of Phathom Pharmaceuticals?
Phathom's primary product is VOQUEZNA, a first-in-class potassium-competitive acid blocker used for treating GERD.
How does Phathom Pharmaceuticals aim to grow?
The company plans to enhance its commercial momentum by leveraging the expertise of its board members and focusing on innovative treatments for gastrointestinal diseases.
Where is Phathom Pharmaceuticals headquartered?
Phathom Pharmaceuticals is based in Florham Park, New Jersey, where it operates its research and development efforts.
How can I contact Phathom Pharmaceuticals for more information?
You can reach the company through media or investor contacts provided in their official communications.
